| Date of Diagnosis | Sample Collection | Prednisone, mg/day | Other Immunosuppression, mg/day | Last Period of Active Disease before ETP | Relapse after ETP | ETP, % | Thrombosis after ETP | Comments |
|---|---|---|---|---|---|---|---|---|
| 1-5-2003 | 10-7-2007 | No | AZA 125 | 25-10-2005 | 163.4 | |||
| 1-8-2004 | 23-5-2006 | No | AZA 150 | 1-6-2005 | 153.9 | |||
| 1-8-1999 | 28-11-2007 | No | No | 5-2-2005 | 1-2-2012 | 129.8 | DVT before ETP** | |
| 1-4-2001 | 19-11-2007 | No | No | 1-4-2001 | 104.2 | |||
| 1-5-2005 | 7-8-2007 | No | No | 1-5-2005 | 16-6-2009 | 160.3 | ||
| 1-5-2005 | 27-11-2007 | No | No | 1-5-2005 | 132.3 | MI 1-8-2012 | ||
| 1-6-1996 | 4-9-2007 | No | No | 9-8-2004 | 9-9-2011 | 139.0 | ||
| 1-6-1994 | 7-3-2006 | No | No | 1-6-1994 | 174.7 | 1-6-2011 DVT | DVT before ETP** | |
| 1-7-2004 | 26-6-2007 | No | No | 1-7-2004 | 174.2 | |||
| 1-1-2000 | 10-7-2007 | No | No | 1-1-2000 | 145.4 | |||
| 1-6-2001 | 30-10-2007 | No | MMF 1000 | 9-8-2006 | 76.8 | |||
| 1-8-2006 | 31-7-2007 | No | MMF 1000 | 1-8-2006 | 125.0 | |||
| 1-1-2004 | 22-1-2008 | 10 | MMF 2000 | 1-8-2006 | 1-1-2011 | 137.1 | ||
| 1-6-1991 | 4-9-2007 | 10 | MTX 15/week | 1-4-2007 | 131.3 | |||
| 1-11-2000 | 26-6-2007 | 12.5 | MMF 1000 | 7-2-2006 | 26-4-2011 | 119.0 | ||
| 1-8-2002 | 26-6-2007 | 17.5 | No | 1-2-2007 | 1-1-2010 | 139.3 | ||
| 1-1-2006 | 3-8-2006 | 2.5 | AZA 100 | 1-1-2006 | 1-12-2006 | 122.9 | 20-12-2006 DVT | |
| 1-5-2000 | 19-6-2007 | 2.5 | AZA 25 | 1-5-2000 | 26-9-2009 | 113.2 | ||
| 1-12-2004 | 19-6-2007 | 2.5 | AZA 75 | 25-8-2005 | 107.8 | |||
| 1-2-2000 | 24-10-2006 | 2 | MTX 10/week | 1-2-2000 | 154.4 | |||
| 1-7-2002 | 19-6-2007 | 3 | No | 11-1-2005 | 174.2 | |||
| 1-1-1999 | 19-6-2007 | 5 | No | 3-3-2003 | 27-8-2010 | 142.5 | ||
| 1-6-2002 | 24-7-2007 | 5 | AZA 100 | 1-3-2006 | 1-8-2012 | 128.3 | ||
| 1-5-2006 | 13-11-2007 | 5 | AZA 100 | 1-5-2006 | 177.1 | 14-4-2009 DVT | ||
| 1-6-1997 | 11-12-2007 | 5 | AZA 150 | 1-10-2001 | 181.9 | DVT before ETP** | ||
| 1-6-1995 | 10-7-2007 | 5 | AZA 75 | 30-8-2005 | 6-4-2012 | 93.7 | ||
| 1-6-1999 | 6-11-2007 | 5 | MTX 15/week | 1-12-2003 | 109.7 | 1-2-2010 PE | ||
| 1-9-2005 | 19-6-2007 | 2.5 | MMF 500 | 1-9-2005 | 30-10-2007 | * | Aortic valve | |
| 1-12-2003 | 16-4-2007 | 3 | AZA 75 | 1-12-2003 | * | TIA | ||
| 1-1-1998 | 19-6-2007 | 5 | MTX 15/week | 1-1-1998 | * | DVT before ETP** | ||
| 1-6-1997 | 23-10-2007 | 7 | MTX 15/week | 1-1-1999 | * | DVT before ETP** |
↵* These patients used vitamin K antagonists during ETP measurement, therefore ETP measurement was not reliable.
↵** Patients included who had had a DVT in the past, had always had this DVT > 6 months before ETP measurement. ETP: endogenous thrombin potential; DVT: deep venous thrombosis; PE: pulmonary embolism; MI: myocardial infarction; TIA: transient ischemic attack.